Utilization and access to antiretroviral genotypic resistance testing and results within the US Department of Veterans Affairs

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 1, 2006, Pages 59-62

  Goetz, Matthew Bidwell ^a,b   Holodniy, Mark ^c,d,e   Poulton, June S ^f,g   Rodriguez, Fred H ^h   Rigsby, Michael O ^e,f,g  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d STANFORD UNIVERSITY   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

^f VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^g YALE UNIVERSITY   (United States)

^h LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Data collection; Drug resistance; Genotype; HIV infections; Veterans

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; ELECTRONIC MEDICAL RECORD; GENOTYPE; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HEALTH CENTER; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LABORATORY TEST; PATIENT CARE; PATIENT COMPLIANCE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOLDIER; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; UNITED STATES; VIRUS GENE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV; HIV INFECTIONS; MEDICAL RECORDS; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 28944448865     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000187445.76579.08     Document Type: Article

References (21)

1. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113-128.
2. Pozniak A, Gazzard B, Anderson J, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2003;4(Suppl 1):1-41.
3. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 29, 2004. Available at: http://www.aidsinfo.nih.gov/guidelines/adult/ AA_102904.pdf.
4. Vandamme AM, Sonnerborg A, Ait-Khaled M, et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther. 2004;9:829-848.
5. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med. 2004;12:119-124.
6. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023-1035.
7. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 4, 2002. Available at: http://www.aidsinfo.nih.gov/guidelines/adult/ archive/AA_020402.pdf.
8. Hertogs K, Bloor S, De Vroey V, et al. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother. 2000;44:568-573.
9. Parkin NT, Chappey C, Petropoulos C. High-level resistance to HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the absence of known resistance mutations [abstract H-451]. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, 2003.
10. Brun-Vezinet F, Costagliola D, Khaled MA, et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther. 2004;9:465-478.
11. DeMasi R, Melby T, Miralles D, et al. Comparison of original and updated genotypic and phenotypic susceptibility algorithms for treatment-experienced patients. Antivir Ther. 2004;9(Suppl):S128.
12. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-480.
13. Pillay D, Mandalia S, Torti C, et al. Prognostic significance of HIV-1 resistance tests is enhanced by consideration of multiple test results [abstract 593]. Presented at: Ninth Conference on Retroviruses and Opportunistic Infections; Seattle, 2002.
14. O'Connell R, Poljak A, Powsner S. Forms that inform. Methods Inf Med. 2004;43:267-275.
15. Powsner S, Costa J, Homer R. Clinicians are from Mars and pathologists are from Venus. Clinician interpretation of pathology reports. Arch Pathol Lab Med. 2000;124:1040-1046.
16. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002;16:209-218.
17. Badri SM, Adeyemi OM, Max BE, et al. How does expert advice impact genotypic resistance testing in clinical practice? Clin Infect Dis. 2003;37:708-713.
18. Perlin JB, Kolodner RM, Roswell RH. The Veterans Health Administration: quality, value, accountability, and information as transforming strategies for patient-centered care. Am J Manag Care. 2004;10:828-836.
19. Wagner EH. Chronic disease management: what will it take to improve care for chronic illness? Eff Clin Pract. 1998;1:2-4.
20. Salama C, Policar M, Cervera C. Knowledge of genotypic resistance mutations among providers of care to patients with human immunodeficiency virus. Clin Infect Dis. 2003;36:101-104.
21. Salama C. Clinician knowledge and attitudes towards genotypic testing. Antivir Ther. 2003;8(Suppl):S123.